The GMRF Clinical Trials Unit is currently recruiting for the following clinical trials in genitourinary cancer:
Protocol: MK-5684-01A (PI: Dr Jeffrey GOH)
Protocol Title: MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-Based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lay Title: The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.
Click here for more information
PROTOCOL: BGB-A317-3111-10188-101 (PI: Jeffrey Goh) (PART E (OVARIAN) ONLY)
Protocol Title: A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined with Zanubrutinib in Patients with Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors.
Lay Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab